Newsroom

09-01-2018

ACCORD HEALTHCARE ANNOUNCES EUROPEAN COMMISSION APPROVAL AND COMPLETION OF ITS PURCHASE OF A BASKET OF PRODUCTS FROM TEVA

Accord Healthcare is pleased to announce EC approval has been granted for its purchase of European Economic Area (EEA) rights to a basket of 13 products from TEVA.  

Read More
12-12-2017

Accord Healthcare – Agile Supply in a Crowded Market

Following a major acquisition of another leading generic pharmaceutical company, Accord Healthcare looks to continue to supply the generic medicine industry while mitigating the risks that come with acquisitions.

Read More
29-11-2017

Accord Healthcare in the Spotlight of New Statesman magazine, the supplement dedicated to Healthcare

In an article dedicated to the generic medicines and the invaluable role they play, James Burt – Executive Vice-president of Accord Healthcare Europe and MENA – talks about how generics provide better value to taxpayers and better outcomes for the patients.

Read More
09-01-2017

Intas completes deal

Intas Pharmaceuticals completes deal to acquire Actavis UK & Ireland generics businesses.

Read More
20-12-2016

Imatinib Accord Launch

Accord Healthcare launches Imatinib Accord 100 mg and 400 mg in the UK.

Read More
05-10-2016

Intas recent acquisition

Intas Pharmaceuticals acquires the generics business of Actavis in the UK & Ireland

Read More
14-01-2014

Clinigen Group extends Exclusive Agreement with Accord Healthcare to Supply Anti-Cancer Drug Capecitabine into Clinical Trials in Europe

Burton-on-Trent, UK – 14 January 2014 - Clinigen Group plc (AIM: CLIN) today announced that its Clinical Trials Supply business (Clinigen CTS) has extended its exclusive European Union (EU) clinical trial distribution agreement with Accord Healthcare (‘Accord’), to include Capecitabine, an orally administered chemotherapeutic tablet.

Read More